Epicept Corporation - Sales Analysis Snapshot

Business Description
This Report provides a comprehensive Sales & Margin summary analysis for Epicept Corporation Tabular results include up to a ten-year history on Sales, EBITDA (Earnings before Interest, Taxes, Depreciation and Amortization), Income before Extraordinary Items and number of Employees. Additional ratios are included for sales growth, earnings and income as a percent of sales and Sales per Employee.

Epicept Corporation. The Group's principal activity is to develop and commercialize pharmaceutical products for the treatment of cancer and pain. The lead product is Ceplene(R), which when used concomitantly with interleukin-2 or IL-2, is intended as remission maintenance therapy in the treatment of acute myeloid leukemia or AML for adult patients who are in their first complete remission. In addition to Ceplene(R), it has two oncology compounds and a pain product candidate for the treatment of peripheral neuropathies in clinical development. Its cancer portfolio includes Crinobulin, or EPC2407, a novel small molecule vascular disruption agent and apoptosis inducer for the treatment of patients with solid tumors and lymphomas. Its late-stage pain product candidate, EpiCeptTM NP-1 Cream is a prescription topical analgesic cream designed to provide effective long-term relief of pain associated with peripheral neuropathies. It operates in the Unites States and Germany.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report